Reuters logo
7 months ago
BRIEF-Redhill Biopharma announces QIDP fast-track designation granted by FDA to RHB-104 for nontuberculous mycobacteria infections
January 11, 2017 / 1:48 PM / 7 months ago

BRIEF-Redhill Biopharma announces QIDP fast-track designation granted by FDA to RHB-104 for nontuberculous mycobacteria infections

Jan 11 (Reuters) - Redhill Biopharma Ltd

* Redhill Biopharma announces QIDP fast-track designation granted by FDA to RHB-104 for nontuberculous mycobacteria infections

* Redhill Biopharma says if approved for treatment of NTM infections, RHB-104 to receive additional 5 yrs of U.S. market exclusivity on top of standard exclusivity period Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below